Posterior reversible encephalopathy syndrome in autoimmune disorders

Koltsov I.A.; Shchukin I.A.; Fidler M.S.; Yasamanova A.N.; Aryasova I.K.; Boyko A.N.

doi:https://doi.org/10.17116/jnevro202412407250

Close metadata

Recommended articles:

Differential diagnosis of Alzheimer’s disease and vascular cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35

Epileptogenesis and risk factors of symptomatic epileptic seizures in patients with acute cerebrovascular accidents. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):26-31

Therapeutic potential of quercetin and its derivatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

Painful diabetic polyneuropathy in patients with cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):64-72

Dynamics of permeability of the blood-brain barrier after FUS thalamotomy according to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60

TERTp mutation screening using digital droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95

Markers of inflammation and angiogenesis in patients with ischemic stroke after the new coronavirus infection. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):100-103

Dynamics of circulatory disease prevalence rates in the working-age population of the regions of the Ural Federal District in 2012—2023. Russian Journal of Preventive Medicine. 2026;(1):14-19

Preeclampsia: a neurogenic conflict between mother and fetus. Russian Bulletin of Obstetrician-Gynecologist. 2026;(1):63-70

Abstract:

Posterior reversible encephalopathy syndrome (PRES) is characterized by nonspecific symptoms, including not only pronounced non-focal and various focal neurological signs but also specific neuroimaging features, including vasogenic edema affecting predominantly the posterior area. PRES usually develops in the setting of acute arterial hypertension. However, it is not uncommon for PRES to develop in non-hypertensive patients, including people with autoimmune disorders (multiple sclerosis, neuromyelitis optica spectrum disorder, etc). PRES could also be due to the toxic effects of drugs or other substances. The pathophysiological mechanisms of PRES include impaired autoregulation of cerebral blood flow due to acute arterial hypertension and toxic endotheliotropic effects of endogenous and exogenous factors.

Keywords:

posterior reversible encephalopathy syndrome

PRES

cerebrovascular diseases

blood-brain barrier

Authors:

Koltsov I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies of the Federal Medical and Biological Agency of Russia

ORCID: 0000-0002-9900-4073

Shchukin I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

ORCID: 0000-0002-6308-9706

Fidler M.S.

Pirogov Russian National Research Medical University

ORCID: 0000-0001-6464-521X

Yasamanova A.N.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-4618-922X

Aryasova I.K.

Pirogov Russian National Research Medical University

ORCID: 0009-0003-0160-8747

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

SPIN RSCI: 9921-9109
Scopus AuthorID: 7102247663
ORCID: 0000-0002-2975-4151

Received:

28.05.2024

Accepted:

29.05.2024

Close metadata

References:

Skvortsova VI, Gubskiy LV, Melnikova EA. Posterior reversible encephalopathy syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(5):104-109. (In Russ.).
Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. NEJM. 1996;334(8):494-500. https://doi.org/10.1056/NEJM199602223340803
Lee VH, Wijdicks EFM, Manno EM, et al. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205-210. https://doi.org/10.1001/archneurol.2007.46
Thavamani A, Umapathi KK, Puliyel M, et al. Epidemiology, Comorbidities, and Outcomes of Posterior Reversible Encephalopathy Syndrome in Children in the United States. Pediatr Neurol. 2020;103:21-26. https://doi.org/10.1016/j.pediatrneurol.2019.07.007
Raj S, Overby P, Erdfarb A, et al. Posterior reversible encephalopathy syndrome: incidence and associated factors in a pediatric critical care population. Pediatr Neurol. 2013;49(5):335-339. https://doi.org/10.1016/j.pediatrneurol.2013.06.007
Ansari B, Saadatnia M. Prevalence and Risk Factors of Posterior Reversible Encephalopathy Syndrome in Isfahan, Iran. Adv Biomed Res. 2021;10:53. https://doi.org/10.4103/abr.abr_243_19
Martynov MYu, Gudkova VV, Koltsova EA, et. al. Arterial Hypertension and Posterior Reversible Encephalopathy Syndrome. Terapiya. 2022;8(9):68-74. (In Russ.). https://doi.org/10.18565/therapy.2022.9.68-74
Aygün BK, Baykuş Y, Berilgen S, et al. Posterior Reversible Encephalopathy Syndrome in severe preeclampsia: case report and literature review. J Turk Ger Gynecol Assoc. 2010;11(4):216-219. https://doi.org/10.5152/jtgga.2010.41
Ganesh K, Nair RR, Kurian G, et al. Posterior Reversible Encephalopathy Syndrome in Kidney Disease. Kidney Int Rep. 2017;3(2):502-507. https://doi.org/10.1016/j.ekir.2017.10.017
Musioł K, Waz S, Boroń M, et al. PRES in the course of hemato-oncological treatment in children. Childs Nerv Syst. 2018;34(4):691-699. https://doi.org/10.1007/s00381-017-3664-y
Bilir ÖA, Dikme G, Malbora B, et al. Posterior Reversible Encephalopathy Syndrome in Childhood Hematological/Oncological Diseases: Multicenter Results. J Pediatr Hematol Oncol. 2021;43(4):e462-e465. https://doi.org/10.1097/MPH.0000000000001965
Racchiusa S, Mormina E, Ax A, Musumeci O, et al. Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2019;40(5):915-922. https://doi.org/10.1007/s10072-018-3651-4
Gatla N, Annapureddy N, Sequeira W, et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2013;19(6):334-340. https://doi.org/10.1097/RHU.0b013e3182a21ffd
Parikh T, Shifteh K, Lipton ML, et al. Deep Brain Reversible Encephalopathy: Association with Secondary Antiphospholipid Antibody Syndrome. AJNR Am J Neuroradiol. 2007;28(1):76-78.
Hegde R, Ismail R, Vegunta A, et al. Atypical posterior reversible encephalopathy syndrome in a case of thrombotic thrombocytopenic purpura with Sjogren’s syndrome. Radiol Case Rep. 2021;16(6):1552-1556. https://doi.org/10.1016/j.radcr.2021.03.035
Chow S, Patnana S, Gupta NK. Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn’s Disease on Infliximab. J Clin Gastroenterol. 2016;50(8):687. https://doi.org/10.1097/MCG.0000000000000557
Navinan MR, Subasinghe CJ, Kandeepan T, et al. Polyarteritis nodosa complicated by posterior reversible encephalopathy syndrome: a case report. BMC Res Notes. 2014;7:89. https://doi.org/10.1186/1756-0500-7-89
Sharma A, Tyagi A, Singal A. Posterior reversible encephalopathy syndrome in Wegener’s granulomatosis: A rare occurrence. Indian J Anaesth. 2020;64(6):538-539. https://doi.org/10.4103/ija.IJA_924_19
Machiraju PK, Alex NM, Safinaaz, Sankaran S. Posterior reversible encephalopathy syndrome as the first manifestation of mixed connective tissue disorder: a case report. J Med Case Reports. 2021;15:40. https://doi.org/10.1186/s13256-021-02678-9
Hussain Awan M, Samreen S, Perveen S, et al. Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis. Rheumatol Immunol Res. 2023;4(2):98-101. https://doi.org/10.2478/rir-2023-0014
Mastorodemos VC, Ioannidis SG, Papadaki EZ, et al. Posterior Reversible Encephalopathy Syndrome, Multiple Sclerosis and interferon therapy: Association, co-incidence or convoluted interplay? Mult Scler Relat Disord. 2020;45:102356. https://doi.org/10.1016/j.msard.2020.102356
Shima T, Tsujino S, Yamashita K, et al. Neuromyelitis Optica Spectrum Disorder Complicated by Posterior Reversible Encephalopathy Syndrome as an Initial Manifestation. Intern Med. 2020;59(15):1887-1890. https://doi.org/10.2169/internalmedicine.4226-19
de Havenon A, Joos Z, Longenecker L, et al. Posterior reversible encephalopathy syndrome with spinal cord involvement. Neurology. 2014;83(22):2002-2006. https://doi.org/10.1212/WNL.0000000000001026
Anderson RC, Patel V, Sheikh-Bahaei N, et al. Posterior Reversible Encephalopathy Syndrome (PRES):Pathophysiology and Neuro-Imaging. Front Neurol. 2020;11:463. https://doi.org/10.3389/fneur.2020.00463
Marra A, Vargas M, Striano P, et al. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014;82(5):619-622. https://doi.org/10.1016/j.mehy.2014.02.022
Adair TH, Montani JP. Angiogenesis. Morgan & Claypool Life Sciences; 2010. Access. 20.05.24. https://www.ncbi.nlm.nih.gov/books/NBK53242/
Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-248. https://doi.org/10.1038/35025215
Felcht M, Luck R, Schering A, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012;122(6):1991-2005. https://doi.org/10.1172/JCI58832
Blanco R, Gerhardt H. VEGF and Notch in Tip and Stalk Cell Selection. Cold Spring Harb Perspect Med. 2013;3(1):a006569. https://doi.org/10.1101/cshperspect.a006569
Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem. 2001;49(4):419-432. https://doi.org/10.1177/002215540104900401
Brindle NPJ, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res. 2006;98(8):1014-1023. https://doi.org/10.1161/01.RES.0000218275.54089.12
Lenting PJ, Casari C, Christophe OD, et al. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost. 2012;10(12):2428-2437. https://doi.org/10.1111/jth.12008
Rauch A, Wohner N, Christophe OD, et al. On the Versatility of von Willebrand Factor. Mediterr J Hematol Infect Dis. 2013;5(1):e2013046. https://doi.org/10.4084/MJHID.2013.046
Romani de Wit T, Rondaij MG, Hordijk PL, et al. Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol. 2003;23(5):755-761. https://doi.org/10.1161/01.ATV.0000069847.72001.E8
Rondaij MG, Bierings R, Kragt A, et al. Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2006;26(5):1002-1007. https://doi.org/10.1161/01.ATV.0000209501.56852.6c
van Agtmaal EL, Bierings R, Dragt BS et al. The Shear Stress-Induced Transcription Factor KLF2 Affects Dynamics and Angiopoietin-2 Content of Weibel-Palade Bodies. Plos One. 2012;7(6):e38399. https://doi.org/10.1371/journal.pone.0038399
Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118(4):771-780. https://doi.org/10.1242/jcs.01653
Koltsov IA, Shchukin IA, Chubykin VI, Fidler MS. Neuroinflammation and Thromboinflammation in Cerebrovascular Disease and Vascular Cognitive Impairment. Terapiya. 2022;8(9):61-66. (In Russ.). https://doi.org/10.18565/therapy.2022.9.75-81
Koltsov IA, Martynov MYu, Yasamanova AN, et al. Influence of von Willebrand factor on common pathophysiological mechanisms of cerebrovascular diseases and multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;1 3 (1S):62-68. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1S-62-68
Lee SW, Kim WJ, Jun HO, et al. Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. Int J Mol Med. 2009;23(2):279-284.
Gurnik S, Devraj K, Macas J, et al. Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathol (Berl). 2016;131(5):753-773. https://doi.org/10.1007/s00401-016-1551-3
Solar P, Hendrych M, Barak M, et al. Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions. Front Cell Neurosci. 2022;16:34-39. https://doi.org/10.3389/fncel.2022.922181
Van Hulle C, Ince S, Okonkwo OC, et al. Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease. Transl Psychiatry. 2024;14 (1):1-8. https://doi.org/10.1038/s41398-023-02706-w
Gewirtz AN, Gao V, Parauda SC, et al. Posterior Reversible Encephalopathy Syndrome. Curr Pain Headache Rep. 2021;25(3):19. https://doi.org/10.1007/s11916-020-00932-1
Proescholdt MA, Jacobson S, Tresser N, et al. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol. 2002;61(10):914-925. https://doi.org/10.1093/jnen/61.10.914
Amini Harandi A, Siavoshi F, Shirzadeh Barough S, et al. Vascular Endothelial Growth Factor as a Predictive and Prognostic Biomarker for Multiple Sclerosis. Neuroimmunomodulation. 2022;29(4):476-485. https://doi.org/10.1159/000525600
Largeau B, Le Tilly O, Sautenet B, et al. Arginine Vasopressin and Posterior Reversible Encephalopathy Syndrome Pathophysiology: the Missing Link? Mol Neurobiol. 2019;56(10):6792-6806. https://doi.org/10.1007/s12035-019-1553-y
Largeau B, Bergeron S, Auger F. et al., Experimental Models of Posterior Reversible Encephalopathy Syndrome: A Review From Pathophysiology to Therapeutic Targets. Stroke. 2024;55(2):484-493. https://doi.org/10.1161/STROKEAHA.123.044533
McKinney AM, Sarikaya B, Gustafson C, et al. Detection of microhemorrhage in posterior reversible encephalopathy syndrome using susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2012;33(5):896-903. https://doi.org/10.3174/ajnr.A2886
Appiani F, Claverie CS, Klein FR. Posterior Reversible Leukoencephalopathy With Hemorrhagic Features: A Case Series. Cureus. 2023;15(11):e49587. https://doi.org/10.7759/cureus.49587
Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. Am J Neuroradiol. 2008;29(6):1036-1042. https://doi.org/10.3174/ajnr.A0928
Pilato F, Distefano M, Calandrelli R. Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Considerations. Front Neurol. 2020;11:34-37. https://doi.org/10.3389/fneur.2020.00034
Triplett JD, Kutlubaev MA, Kermode AG, et al. Posterior reversible encephalopathy syndrome (PRES):diagnosis and management. Pract Neurol. 2022;22(3):183-189. https://doi.org/10.1136/practneurol-2021-003194
Morrow SA, Rana R, Lee D, et al. Posterior Reversible Encephalopathy Syndrome due to High Dose Corticosteroids for an MS Relapse. Case Rep Neurol Med. 2015;12:325657. https://doi.org/10.1155/2015/325657
Dietz N, Mufti Z, Yousaf M, et al. Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72 h after cessation of interferon-beta therapy with sub-clinical inflammation. BMC Neurol. 2021;21(1):445. https://doi.org/10.1186/s12883-021-02471-7
Lindå H, von Heijne A. A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis. Front Neurol. 2015;6:39. https://doi.org/10.3389/fneur.2015.00039
Décard BF, Haghikia A, Tönnes C, et al. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Mult Scler Houndmills Basingstoke Engl. 2013;19 (2):249-251. https://doi.org/10.1177/1352458512448268
Magaña SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72(8):712-717. https://doi.org/10.1212/01.wnl.0000343001.36493.ae
Matiello M, Muralidharan R, Sun D, et al. Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4. Neurol Genet. 2015;1(2):e 19. https://doi.org/10.1212/NXG.0000000000000013
Corbett J, Bhuta S, Prain K, et al. PRES-like presentation in MOG antibody-related demyelination (MARD). J Clin Neurosci Off J Neurosurg Soc Australas. 2020;72:453-455. https://doi.org/10.1016/j.jocn.2020.01.034
Zou LP, Liu LY, Li H, et al. Establishment and utility assessment of posterior reversible encephalopathy syndrome early warning scoring (PEWS) scale establishment and utility assessment of PEWS scale. BMC Neurol. 2019;19(1):30. https://doi.org/10.1186/s12883-019-1247-0
Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. https://doi.org/10.1016/S1474-4422(15)00111-8
Hinduja A. Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome. Front Neurol. 2020;11:71. https://doi.org/10.3389/fneur.2020.00071
Legriel S, Schraub O, Azoulay E, et al. Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS). Determinants of Recovery from Severe Posterior Reversible Encephalopathy Syndrome. PLoS ONE. 2012;7(9):e44534. https://doi.org/10.1371/journal.pone.0044534
Liu L, Dai D, Cao F, et al. Posterior reversible encephalopathy syndrome with spinal cord involvement but without hemisphere lesions. Medicine (Baltimore). 2019;98(2):e13649. https://doi.org/10.1097/MD.0000000000013649
Hugonnet E, Da Ines D, Boby H, et al. Posterior reversible encephalopathy syndrome (PRES):features on CT and MR imaging. Diagn Interv Imaging. 2013;94(1):45-52. https://doi.org/10.1016/j.diii.2012.02.005
Burdette JH, Elster AD, Ricci PE. Acute cerebral infarction: quantification of spin-density and T2 shine-through phenomena on diffusion-weighted MR images. Radiology. 1999;212(2):333-339. https://doi.org/10.1148/radiology.212.2.r99au36333
Parauda SC, Zhang C, Salehi Omran S, et al. Risk of Stroke After Posterior Reversible Encephalopathy Syndrome. Stroke. 2022;53(11):3313-3319. https://doi.org/10.1161/STROKEAHA.122.038673
Fazeli S, Noorbakhsh A, Imbesi SG, et al. Cerebral perfusion in posterior reversible encephalopathy syndrome measured with arterial spin labeling MRI. NeuroImage Clin. 2022;35:103017. https://doi.org/10.1016/j.nicl.2022.103017
Hedna VS, Stead LG, Bidari S, et al. Posterior reversible encephalopathy syndrome (PRES) and CT perfusion changes. Int J Emerg Med. 2012;5:12. https://doi.org/10.1186/1865-1380-5-12
Cho S, Lee MJ, Chung CS. Effect of Nimodipine Treatment on the Clinical Course of Reversible Cerebral Vasoconstriction Syndrome. Front Neurol. 2019;10:644. https://doi.org/10.3389/fneur.2019.00644
Yıldırım Eryılmaz N, Ocakoglu G. Comparison of magnesium sulfate and mannitol in treatment of eclamptic women with posterior reversible encephalopathy syndrome. Arch Gynecol Obstet. 2012;286(2):287-293. https://doi.org/10.1007/s00404-012-2268-8
Parikh NS, Schweitzer AD, Young RJ, et al. Corticosteroid Therapy and Severity of Vasogenic Edema in Posterior Reversible Encephalopathy Syndrome. J Neurol Sci. 2017;380:11-15. https://doi.org/10.1016/j.jns.2017.06.044
Shibata T, Hashimoto N, Mase M. Intracranial hemorrhage in posterior reversible encephalopathy syndrome due to corticosteroid pulse therapy. Brain Disord. 2022;7:100040. https://doi.org/10.1016/j.dscb.2022.100040
Meyer M, Niemöller U, Stein T, et al. Positive Effect of Steroids in Posterior Reversible Encephalopathy Syndrome. Case Rep Neurol. 2019;11(2):173-177. https://doi.org/10.1159/000500410
Arslan Zİ, Turna CK, Özerdem ÇY, et al. Treatment of Posterior Reversible Encephalopathy Syndrome that Occurred in a Patient with Systemic Lupus Erythematosus by Plasmapheresis. Turk J Anaesthesiol Reanim. 2015;43(4):291-294. https://doi.org/10.5152/TJAR.2015.13540
Demirel İ, Kavak BS, Özer AB, et al. An intensive care approach to posterior reversible encephalopathy syndrome (PRES):An analysis of 7 cases. J Turk Ger Gynecol Assoc. 2014;15(4):217-221. https://doi.org/10.5152/jtgga.2014.14072
Shadman J, Sadeghian N, Moradi A, et al. Magnesium sulfate protects blood-brain barrier integrity and reduces brain edema after acute ischemic stroke in rats. Metab Brain Dis. 2019;34(4):1221-1229. https://doi.org/10.1007/s11011-019-00419-y
Seitz A, Parauda SC, Salehi Omran Set al. Long-term risk of seizure after posterior reversible encephalopathy syndrome. Ann Clin Transl Neurol. 2023;10(4):610-618. https://doi.org/10.1002/acn3.51748
Receivd 28.05.2024